References
- Brickl R., Schmid J., Koss F. W. Considerations on pharmacokinetics of psoralens after oral administration and conclusions for therapy. Psoralens in Cosmetics and Dermatology, J. Cahn, P. Forlot, C. Grupper, A. Maybeck, F. Urbach. Pergamon, Paris 1981; 263–268
- Brodie R. R., Irons S. R., Chasseaud L. F., Taylor T., Morris G. R., Baker J. M., Forlot P. Bioavailability of 5-methoxypsoralen (5-MOP) from formulations containing the micronised and unmicronised drug. Psoralens—Past, Present and Future of Photochemoprotection and other Biological Activities, T. B. Fitzpatrick, P. Forlot, M. A. Pathak, F. Urbach. John Libbey Eurotext, Paris 1989; 263–268
- Brodie R. R., Mayo B. C., Chasseaud L. F., Hawkins D. R. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbonate (ciclobendazole) to rats and dogs. Arzneinittel-Forschung 1977; 27: 593–598
- Busch U., Schmid F., Koss F. W., Zipp H., Zimmer A. Pharmacokinetics and metabolite pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog. Archives of Dermatological Research 1978; 262: 255–265
- Chasseaud L. F., Hawkins D. R., Fry B. J., Lewis J. D., Saggers V. H., Sword I. P. The metabolic fate of the coronary dilator 4-(3,4,5-trimethyoxycinnamoyl)-1-(N-isopropylcarbamoylmethyl)-piperazinthe rat, dog and man. Xenobiotica 1974; 4: 393–407
- De Wolff F. A., Thomas T. V. Clinical pharmacokinetics of methoxalen and other psoralens. Clinical Pharmacokinetics 1986; 11: 62–75
- Grupper C., Berretti B. The Aubervilliers PUVA Study. Psoralens in Cosmetics and Dermatology, J. Cahn, P. Forlot, C. Grupper, A. Maybeck, F. Urbach. Pergamon, Paris 1981; 223–232
- Hawkins D. R., Chasseaud L. F., Woodhouse R. N., Cresswell D. G. The distribution, excretion and biotransformation of p-dichloro(14C)benzene in rats after repeated inhalation, oral and subcutaneous doses. Xenobiotica 1980; 10: 81–95
- Hönigsmann H., Jaschke E., Gschnaif F., Brenner W., Fritsch P., Wolff K. 5-methoxypsoralen (bergapten) in photochemotherapy of psoriasis. British Journal of Dermatology 1979; 101: 369–378
- Kolis S. J., Williams T. H., Postma E. J., Sasso G. J., Confalone P. N., Schwarz M. A. The metabolism of 14C-methoxalen by the dog. Drug Metabolism and Disposition 1979; 7: 220–225
- Marks R. Sunscreens. Prescribers Journal 1984; 24: 32–37
- Mays D. C., Hecht S. G., Unger S. E., Pacula C. M., Climie J. M., Sharp D. E., Gerber N. Disposition of 8-methoxypsoralen in the rat. Induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. Drug Metabolism and Disposition 1987; 15: 318–328
- Midgley I., Hawkins D. R., Chasseaud L. F. The metabolic fate of the antidepressive agent amitriptylinoxide in man. Arzneimittel-Forschung 1978; 28: 1911–1916
- Mitchell J. R., Nelson W. L., Potter W. Z., Sasame H. A., Jollow D. J. Metabolic activation of furosemide to a chemically reactive hepatotoxic metabolite. Journal of Pharmacology and Experimental Therapeutics 1976; 199: 41–52
- Nitsche V., Mascher H. 5-methoxypsoralen: Bioverfügbarkeit und Pharmakokinetik. Arzneimittel-Forschung 1982; 32: 1338–1341
- Prognon P., Simon G., Mahuzier G. Dosage du méthoxy-5-psoralène dans le plasma par chromatographie en phase liquide et detection spectrofluoriétrique. Journal of Chromatography 1983; 272: 193–199
- Scheline R. R. Studies on the role of the intestinal microflora in the metabolism of coumarin in rats. Acta Pharmacol et Toxicol 1968; 26: 325–331
- Schmid J., Prox A., Reuter A., Zipp H., Koss F. W. The metabolism of 8-methoxypsoralen in man. European Journal of Drug Metabolism and Pharmacokinetics 1980; 5: 81–92
- Schmid J., Brikl R., Busch U., Koss F. W. Comparison of pharmacokinetics, pharmacodynamics and metabolism of 8-MOP, 5-MOP and TMP. Psoralens in Cosmetics and Dermatology, J. Cahn, P. Forlot, C. Grupper, A. Maybeck, F. Urbach. Pergamon, Paris 1981; 109–116
- Scott B. R., Pathak M. A., Mohn G. R. Molecular and genetic basis of furocoumarin reactions. Mutation Research 1976; 39: 29–74
- Stolk L. M. L., Westerhof W., Cormane R. H., Van Zwieten P. A. Serum and urine concentrations of 5-methoxypsoralen after oral administration. British Journal of Dermatology 1981; 105: 415–421
- Stolk L. M. L., Siddiqui A. H., Westerhog W., Cormane R. H. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen. British Journal of Dermatology 1985; 112: 469–473